OPK vs. FOLD, LGND, BCRX, DVAX, GERN, CLDX, MNKD, MYGN, NVAX, and INVA
Should you be buying OPKO Health stock or one of its competitors? The main competitors of OPKO Health include Amicus Therapeutics (FOLD), Ligand Pharmaceuticals (LGND), BioCryst Pharmaceuticals (BCRX), Dynavax Technologies (DVAX), Geron (GERN), Celldex Therapeutics (CLDX), MannKind (MNKD), Myriad Genetics (MYGN), Novavax (NVAX), and Innoviva (INVA). These companies are all part of the "biotechnology" industry.
OPKO Health vs.
Amicus Therapeutics (NASDAQ:FOLD) and OPKO Health (NASDAQ:OPK) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings, community ranking and analyst recommendations.
64.6% of OPKO Health shares are owned by institutional investors. 2.2% of Amicus Therapeutics shares are owned by insiders. Comparatively, 47.3% of OPKO Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Amicus Therapeutics currently has a consensus target price of $16.75, suggesting a potential upside of 82.26%. OPKO Health has a consensus target price of $2.75, suggesting a potential upside of 63.69%. Given Amicus Therapeutics' higher probable upside, research analysts plainly believe Amicus Therapeutics is more favorable than OPKO Health.
Amicus Therapeutics has higher earnings, but lower revenue than OPKO Health. Amicus Therapeutics is trading at a lower price-to-earnings ratio than OPKO Health, indicating that it is currently the more affordable of the two stocks.
In the previous week, Amicus Therapeutics had 32 more articles in the media than OPKO Health. MarketBeat recorded 33 mentions for Amicus Therapeutics and 1 mentions for OPKO Health. Amicus Therapeutics' average media sentiment score of 0.21 beat OPKO Health's score of 0.00 indicating that Amicus Therapeutics is being referred to more favorably in the media.
Amicus Therapeutics received 26 more outperform votes than OPKO Health when rated by MarketBeat users. Likewise, 72.98% of users gave Amicus Therapeutics an outperform vote while only 65.54% of users gave OPKO Health an outperform vote.
Amicus Therapeutics has a net margin of -10.62% compared to OPKO Health's net margin of -18.65%. Amicus Therapeutics' return on equity of 13.43% beat OPKO Health's return on equity.
Amicus Therapeutics has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500. Comparatively, OPKO Health has a beta of 1.63, suggesting that its stock price is 63% more volatile than the S&P 500.
Summary
Amicus Therapeutics beats OPKO Health on 12 of the 18 factors compared between the two stocks.
Get OPKO Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for OPK and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OPKO Health Competitors List
Related Companies and Tools
This page (NASDAQ:OPK) was last updated on 2/22/2025 by MarketBeat.com Staff
Free OPK Stock Alerts